Abstract
Members of the ErbB subfamily of receptor tyrosine kinases are important
regulators of normal mammary gland physiology, and aberrations in their
signaling have been associated with breast tumorigenesis. Therapeutics
targeting epidermal growth factor receptor (EGFR = ErbB1) or ErbB2 in
breast cancer have been approved for clinical use. In contrast,
relatively little is known about the biological significance of ErbB4
signaling in breast cancer. This review focuses on recent advances in
our understanding about the role of ErbB4 in breast carcinogenesis, as
well as in the potential clinical relevance of ErbB4 in breast cancer
prognostics and therapy.
Original language | English |
---|---|
Pages (from-to) | 259 - 268 |
Number of pages | 10 |
Journal | Journal of Mammary Gland Biology and Neoplasia |
Volume | 13 |
Issue number | 2 |
DOIs | |
Publication status | Published - 2008 |
MoE publication type | A1 Journal article-refereed |
Keywords
- Alternative splicing
- Epidermal growth factor
- Estrogen receptor
- HER4
- Neuregulins
- Targeted therapeutics